Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in ResMed Inc., Illumina or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how ResMed Inc., Illumina and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About ResMed Inc., Illumina and Inc.

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Latest Health Care Equipment & Supplies and ResMed Inc., Illumina, Inc. Stock News

As of September 4, 2026, ResMed Inc. had a $32.9 billion market capitalization, compared to the Health Care Equipment & Supplies median of $423.0 million. ResMed Inc.’s stock is down 5.2% in 2026, down 5% in the previous five trading days and down 16.6% in the past year.

Currently, ResMed Inc.’s price-earnings ratio is 21.9. ResMed Inc.’s trailing 12-month revenue is $5.7 billion with a 26.9% net profit margin. Year-over-year quarterly sales growth most recently was 8.6%. Analysts expect adjusted earnings to reach $12.081 per share for the current fiscal year. ResMed Inc. currently has a 1.2% dividend yield.

As of September 4, 2026, Illumina, Inc. had a $33.0 billion market cap, putting it in the 90th percentile of all stocks. Illumina, Inc.’s stock is up 66.4% in 2026, up 1.2% in the previous five trading days and up 123.4% in the past year.

Currently, Illumina, Inc.’s price-earnings ratio is 40.6. Illumina, Inc.’s trailing 12-month revenue is $4.5 billion with a 18.3% net profit margin. Year-over-year quarterly sales growth most recently was 9.4%. Analysts expect adjusted earnings to reach $5.355 per share for the current fiscal year. Illumina, Inc. does not currently pay a dividend.

How We Compare ResMed Inc., Illumina and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at ResMed Inc., Illumina and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

ResMed Inc., Illumina and Inc. Growth Grades

Company	Ticker	Growth
ResMed Inc.	RMD	A
Illumina, Inc.	ILMN	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

ResMed Inc. has a Growth Score of 89, which is Very Strong. Illumina, Inc. has a Growth Score of 61, which is Strong.

The Growth Grade Winner: ResMed Inc.

As you can clearly see from the Growth Grade breakdown above, ResMed Inc. has a more attractive growth grade than Illumina, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, ResMed Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

ResMed Inc., Illumina and Inc.’s Momentum Grades

Company	Ticker	Momentum
ResMed Inc.	RMD	C
Illumina, Inc.	ILMN	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

ResMed Inc. has a Momentum Score of 41, which is Average. Illumina, Inc. has a Momentum Score of 92, which is Very Strong.

The Momentum Grade Winner: Illumina, Inc.

As you can clearly see from the Momentum Grade breakdown above, Illumina, Inc. is considered to have stronger momentum compared to ResMed Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Illumina, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

ResMed Inc., Illumina and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
ResMed Inc.	RMD	C
Illumina, Inc.	ILMN	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

ResMed Inc. has a Earnings Estimate Score of 53, which is Neutral. Illumina, Inc. has a Earnings Estimate Score of 74, which is Positive.

The Earnings Estimate Revisions Grade Winner: Illumina, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Illumina, Inc. has a better Earnings Estimate Revisions Grade than ResMed Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Illumina, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other ResMed Inc., Illumina and Inc. Grades

In addition to Growth, Estimate Revisions and Momentum, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether ResMed Inc., Illumina and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, ResMed Inc., Illumina or Inc. Stock?

Overall, ResMed Inc. stock has a Growth Score of 89, Momentum Score of 41 and Estimate Revisions Score of 53.

Illumina, Inc. stock has a Growth Score of 61, Momentum Score of 92 and Estimate Revisions Score of 74.

Comparing ResMed Inc., Illumina and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.